This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
ELISA/assay
product name :
PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair
catalog :
EP-101
quantity :
96 tests
price :
600 USD
product information
company name :
ACROBiosystems
product type :
Kits
catalog :
EP-101
product name :
PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair
quantity :
96 tests
price :
600 USD
quantity & price :
$600/96tests
target :
PD-1 & PD-L1
host species :
Human
Research :
For Research Use Only
Formulation :
Please contact us for detailed information.
Reconstitution :
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage :
The unopened kit should be stored at 2°C to 8°C. The shelf life is 12 months from the date of receipt. The opened kit should be stored at 2°C to 8°C. The shelf life is 1 month from the date of opening.
Background :
Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments